Seeking Alpha·Jun 23, 2026
Myomo, Inc. (MYO) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 TranscriptMyomo, Inc. (MYO) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
Myomo, Inc.(MYO)Earnings, Financials & Key Ratios
MYO•NYSE
$1.16
Price updated Jul 7, 2026
AboutMyomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.Show more
- Revenue$41M+25.7%
- EBITDA-$13M-132.7%
- Net Income-$16M-151.9%
- EPS (Diluted)-0.37-131.3%
- Gross Margin65.7%-7.8%
- EBITDA Margin-30.88%-85.1%
- Operating Margin-35.19%-84.5%
- Net Margin-38.05%-100.3%
- ROE-86.24%-135.0%
MYO Price & Volume
Myomo, Inc. (MYO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and cash depletion
Key Thesis Takeaways
- Myomo faces a critical inflection point as its reliance on lumpy insurance authorizations drives volatile revenue growth, which decelerated to 2.9% in 2026Q1.
- Despite maintaining gross margins near 68.2%, the company has failed to achieve operating leverage, with SG&A expenses consistently outpacing gross profit.
- Investors should monitor the company's ability to manage its $19.0M debt load and $11.4M cash reserve, as the current burn rate suggests a high probability of future dilutive financing.
Verdict Logic
the company's TTM net loss of $15.5M relative to its $11.4M cash balance indicates a precarious liquidity position that warrants extreme caution for institutional investors.
MYO Growth Metrics
Myomo, Inc. (MYO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years50.43%
5 Years40.1%
3 Years38.05%
TTM6.68%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-160.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-147.19%
Return on Capital
10 Years-106.71%
5 Years-70.22%
3 Years-60.48%
Last Year-46.19%
Latest MYO News
Recent stock market news and headlines for Myomo, Inc. (MYO)
Business Wire·Jun 16, 2026
Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment ConferenceBURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, taking place June 23–24, 2026. President and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will deliver a presentati.
Peers Comparison
Key metrics vs top competitors for Myomo, Inc. (MYO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.16 | $44.82M | -3.14 | 25.73% | -38.05% | -86.24% | — | |
| $7.58 | $1.98B | -24.45 | 18.96% | -73.63% | -36.79% | — | |
| $9.38 | $1.42B | -9.77 | 24.95% | -21.07% | -443.09% | — | |
| $4.32 | $310.89M | -4.60 | -38.1% | -61.93% | -15.09% | — | |
| $78.83 | $10.63B | 20.11 | 16.65% | 18.92% | 13.04% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — |
Compare MYO vs Peers
Myomo, Inc. (MYO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MYO SEC Filings & Documents
Myomo, Inc. (MYO) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 16, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when MYO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MYO Frequently Asked Questions
Myomo, Inc. (MYO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Myomo, Inc.'s revenue?
Myomo, Inc. (MYO) reported $41.2M in revenue for fiscal year 2025. This represents a 4412% increase from $0.9M in 2014.
How fast is Myomo, Inc. growing?
Myomo, Inc. (MYO) grew revenue by 25.7% over the past year. This is strong growth.
Is MYO profitable?
Myomo, Inc. (MYO) reported a net loss of $15.1M for fiscal year 2025.
Dividend & Returns
What is MYO's return on equity?
Myomo, Inc. (MYO) has a return on equity (ROE) of -86.2%. Negative ROE indicates the company is unprofitable.
What is Myomo, Inc.'s free cash flow?
Myomo, Inc. (MYO) had negative free cash flow of $17.3M in fiscal year 2025, likely due to heavy capital investments.